Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

PURPOSE: Aromatase inhibitor (AI) treatment is the standard of care for postmenopausal women with primary estrogen receptor–positive breast cancer. The impact of duration of neoadjuvant endocrine therapy (NET) on molecular characteristics is still unknown. We evaluated and compared changes of gene e...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergamino, Milana A., Morani, Gabriele, Parker, Joel, Schuster, Eugene F., Leal, Mariana F., López-Knowles, Elena, Tovey, Holly, Bliss, Judith M., Robertson, John F.R., Smith, Ian E., Dowsett, Mitch, Cheang, Maggie C.U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612503/
https://www.ncbi.nlm.nih.gov/pubmed/34965950
http://dx.doi.org/10.1158/1078-0432.CCR-21-2718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612503/
https://www.ncbi.nlm.nih.gov/pubmed/34965950
http://dx.doi.org/10.1158/1078-0432.CCR-21-2718

Ejemplares similares